Sign In
Buy STVN
$19.85
-0.350 (-1.73%)
At Close: Jul 31, 2026
Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026
04:05pm, Thursday, 23'rd Apr 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
ArrowMark Colorado Holdings LLC Grows Position in Stevanato Group S.p.A. $STVN
04:26am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC increased its holdings in Stevanato Group S.p.A. (NYSE: STVN) by 6.7% in the undefined quarter, according to its most recent filing with the SEC. The institutional inve
Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Recommendation of “Moderate Buy” by Analysts
03:25am, Sunday, 15'th Mar 2026
Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
04:45pm, Thursday, 12'th Mar 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
04:28am, Friday, 06'th Mar 2026
Stevanato Group is reiterated as a Buy, supported by strong Q4/FY25 results and robust long-term demand drivers. While the Engineering division continues to weigh on margins and reported less than €
Stevanato Group Q4 Earnings Call Highlights
03:52am, Friday, 06'th Mar 2026
Stevanato Group (NYSE: STVN) executives said the company closed fiscal 2025 with "solid" results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diag
Stevanato Group (NYSE:STVN) Shares Down 8.5% on Analyst Downgrade
01:52am, Friday, 06'th Mar 2026
Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) dropped 8.5% on Thursday after Citigroup lowered their price target on the stock from $32.00 to $26.00. Citigroup currently has a buy ra
Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript
11:32pm, Wednesday, 04'th Mar 2026
Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
08:46am, Wednesday, 04'th Mar 2026
Stevanato Group (STVN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.2 per share a year ago.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Artisan Partners Limited Partnership Has $67.29 Million Stock Holdings in Stevanato Group S.p.A. $STVN
04:25am, Saturday, 28'th Feb 2026
Artisan Partners Limited Partnership trimmed its position in shares of Stevanato Group S.p.A. (NYSE: STVN) by 4.4% in the undefined quarter, according to the company in its most recent Form 13F filing
Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026
06:30am, Thursday, 19'th Feb 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)
01:08am, Monday, 09'th Feb 2026
Stevanato Group (NYSE: STVN - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses
Stevanato Group (NYSE:STVN) Reaches New 52-Week Low – Time to Sell?
01:29am, Sunday, 01'st Feb 2026
Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) hit a new 52-week low on Friday. The stock traded as low as €15.40 and last traded at €16.02, with a volume of 1057900 shares tradin
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
01:22pm, Thursday, 29'th Jan 2026
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were
